INmune Bio Announces $13.0 Million Registered Direct Offering
Boca Raton, Florida, Sept. 13, 2024 ( GLOBE NEWSWIRE ) -- INmune Bio Inc. ( Nasdaq: INMB ) ( the "Company" or "INmune Bio" ) , a clinical-stage inflammation and immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced it ...
| Ticker |
Sentiment |
Impact |
|
ALGGF
|
Neutral
|
8 %
|
|
INMB
|
Neutral
|
25 %
|
|
GLP
|
Neutral
|
8 %
|
